Log in

NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price, Forecast & News

$40.13
-2.33 (-5.49 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$39.97
Now: $40.13
$42.93
50-Day Range
$34.37
MA: $46.04
$58.31
52-Week Range
$33.80
Now: $40.13
$64.94
Volume121,599 shs
Average Volume280,182 shs
Market Capitalization$548.98 million
P/E Ratio40.13
Dividend YieldN/A
Beta1.21
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Read More
Eagle Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EGRX
CUSIPN/A
Phone201-326-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$195.89 million
Cash Flow$1.70 per share
Book Value$13.11 per share

Profitability

Net Income$14.31 million

Miscellaneous

Employees96
Market Cap$548.98 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.


Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

How has Eagle Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Eagle Pharmaceuticals' stock was trading at $39.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EGRX stock has increased by 2.7% and is now trading at $40.13. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Eagle Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Eagle Pharmaceuticals.

When is Eagle Pharmaceuticals' next earnings date?

Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Eagle Pharmaceuticals.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) announced its quarterly earnings data on Monday, March, 2nd. The specialty pharmaceutical company reported $0.48 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.02. The specialty pharmaceutical company had revenue of $48.30 million for the quarter, compared to the consensus estimate of $49.08 million. Eagle Pharmaceuticals had a return on equity of 9.99% and a net margin of 7.31%. Eagle Pharmaceuticals's revenue was down 13.8% compared to the same quarter last year. During the same period last year, the company posted $1.20 EPS. View Eagle Pharmaceuticals' earnings history.

What price target have analysts set for EGRX?

3 Wall Street analysts have issued 12 month price objectives for Eagle Pharmaceuticals' stock. Their forecasts range from $46.00 to $59.00. On average, they expect Eagle Pharmaceuticals' share price to reach $51.67 in the next twelve months. This suggests a possible upside of 28.7% from the stock's current price. View analysts' price targets for Eagle Pharmaceuticals.

What are Wall Street analysts saying about Eagle Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (3/6/2020)
  • 2. Cantor Fitzgerald analysts commented, ". Post 1Q19, we are reiterating our Neutral rating and our 12- month price target on EGRX shares of $58. Pipeline setbacks in 2018 have created an overhang on the visibility of near term growth drivers for EGRX, which keeps us on the sidelines for now. Given the current visibility, we believe EGRX stock remains fairly valued at current levels. That said, EGRX’s current business continues to perform well and the company is advancing Ryanodex for nerve agent exposure and acute radiation syndrome, both of which we believe have the potential to get into the strategic national stockpile, if successful." (5/7/2019)

Has Eagle Pharmaceuticals been receiving favorable news coverage?

News coverage about EGRX stock has trended somewhat negative on Saturday, according to InfoTrie. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eagle Pharmaceuticals earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the next several days. View the latest news aboutEagle Pharmaceuticals.

Are investors shorting Eagle Pharmaceuticals?

Eagle Pharmaceuticals saw a increase in short interest in the month of February. As of February 14th, there was short interest totaling 1,870,000 shares, an increase of 8.1% from the January 30th total of 1,730,000 shares. Based on an average daily trading volume, of 143,500 shares, the short-interest ratio is currently 13.0 days. Currently, 14.4% of the shares of the stock are short sold. View Eagle Pharmaceuticals' Current Options Chain.

Who are some of Eagle Pharmaceuticals' key competitors?

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), Celgene (CELG), Intercept Pharmaceuticals (ICPT), AbbVie (ABBV), GW Pharmaceuticals PLC- (GWPH), bluebird bio (BLUE), Radius Health (RDUS) and Clovis Oncology (CLVS).

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the following people:
  • Mr. Scott L. Tarriff, CEO & Director (Age 59)
  • Mr. David M. Pernock, Pres & Chief Operating Officer (Age 66)
  • Mr. Pete A. Meyers, Chief Financial Officer (Age 49)
  • Dr. Adrian Hepner, Exec. VP & Chief Medical Officer (Age 58)
  • Mr. Daniel O'Connor, Exec. VP of Biologics & Corp. Devel. (Age 39)

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (13.17%), State Street Corp (4.47%), LSV Asset Management (2.70%), Norges Bank (1.82%), Credit Suisse AG (1.77%) and Chartwell Investment Partners LLC (1.38%). Company insiders that own Eagle Pharmaceuticals stock include Douglas L Braunstein, Hudson Executive Capital Lp and Scott Tarriff. View institutional ownership trends for Eagle Pharmaceuticals.

Which institutional investors are selling Eagle Pharmaceuticals stock?

EGRX stock was sold by a variety of institutional investors in the last quarter, including LSV Asset Management, Bank of America Corp DE, FMR LLC, Connor Clark & Lunn Investment Management Ltd., Connor Clark & Lunn Investment Management Ltd., Chicago Equity Partners LLC, Man Group plc, and Oxford Asset Management LLP. Company insiders that have sold Eagle Pharmaceuticals company stock in the last year include Douglas L Braunstein, Hudson Executive Capital Lp, and Scott Tarriff. View insider buying and selling activity for Eagle Pharmaceuticals.

Which institutional investors are buying Eagle Pharmaceuticals stock?

EGRX stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Renaissance Technologies LLC, Goldman Sachs Group Inc., State Street Corp, California Public Employees Retirement System, Schroder Investment Management Group, Janus Henderson Group PLC, and Martingale Asset Management L P. View insider buying and selling activity for Eagle Pharmaceuticals.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $40.13.

How big of a company is Eagle Pharmaceuticals?

Eagle Pharmaceuticals has a market capitalization of $548.98 million and generates $195.89 million in revenue each year. The specialty pharmaceutical company earns $14.31 million in net income (profit) each year or $1.38 on an earnings per share basis. Eagle Pharmaceuticals employs 96 workers across the globe. View additional information about Eagle Pharmaceuticals.

What is Eagle Pharmaceuticals' official website?

The official website for Eagle Pharmaceuticals is http://www.eagleus.com/.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]


MarketBeat Community Rating for Eagle Pharmaceuticals (NASDAQ EGRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  387 (Vote Outperform)
Underperform Votes:  275 (Vote Underperform)
Total Votes:  662
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe EGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: What is Put Option Volume?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel